Biology of Blood and Marrow Transplantation
Volume 14, Issue 5 , Pages 510-517 , May 2008

Preengraftment Serum C-Reactive Protein (CRP) Value May Predict Acute Graft-versus-Host Disease and Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation

Received 29 September 2007 ,Accepted 10 February 2008.

References 

  1. Wojnar J, Giebel S, Krawczyk-Kulis M, et al. Acute graft-versus-host disease. The incidence and risk factors. Ann Transplant. 2006;11:16–23
  2. Weisdorf D, Hakke R, Blazar B, et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation. 1991;51:1197–1203
  3. Krenger W, Hill GR, Ferrara JL. Cytokine cascades in acute graft-versus-host disease. Transplantation. 1997;64:553–558
  4. Ferrara JL. The cytokine modulation of acute graft-versus-host disease. Bone Marrow Transplant. 1998;21(Suppl 3):S13–S15
  5. Cooke KR, Olkiewicz K, Erickson N, Ferrara JL. The role of endotoxin and the innate immune response in the pathophysiology of acute graft versus host disease. J Endotoxin Res. 2002;8:441–448
  6. Toren A, Novick D, Or R, Ackerstein A, Slavin S, Nagler A. Soluble interleukin-6 receptors in hematology patients undergoing bone marrow transplantation. Transplantation. 1996;62:138–142
  7. Liem LM, van Houwelingen HC, Goulmy E. Serum cytokine levels after HLA-identical bone marrow transplantation. Transplantation. 1998;66:863–871
  8. Schwaighofer H, Herold M, Schwarz T, et al. Serum levels of interleukin 6, interleukin 8, and C-reactive protein after human allogeneic bone marrow transplantation. Transplantation. 1994;58:430–436
  9. Chasty RC, Lamb WR, Gallati H, Roberts TE, Brenchley PE, Yin JA. Serum cytokine levels in patients undergoing bone marrow transplantation. Bone Marrow Transplant. 1993;12:331–336
  10. Lange A, Karabon L, Klimczak A, et al. Serum interferon-gamma and C-reactive protein levels as predictors of acute graft-vs-host disease in allogeneic hematopoietic precursor cell (marrow or peripheral blood progenitor cells) recipients. Transplant Proc. 1996;28:3522–3525
  11. Symington FW, Symington BE, Liu PY, Viguet H, Santhanam U, Sehgal PB. The relationship of serum IL-6 levels to acute graft-versus-host disease and hepatorenal disease after human bone marrow transplantation. Transplantation. 1992;54:457–462
  12. Fowler DH, Foley J, Whit-Shan Hou J, et al. Clinical “cytokine storm” as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor alpha with severe gut graft-versus-host disease. Clin Gastroenterol Hepatol. 2004;2:237–245
  13. Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood. 1992;80:2964–2968
  14. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990;265:621–636
  15. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–454
  16. Santolaya ME, Cofre J, Beresi V. C-reactive protein: a valuable aid for the management of febrile children with cancer and neutropenia. Clin Infect Dis. 1994;18:589–595
  17. Manian FA. A prospective study of daily measurement of C-reactive protein in serum of adults with neutropenia. Clin Infect Dis. 1995;21:114–121
  18. Persson L, Engervall P, Magnuson A, et al. Use of inflammatory markers for early detection of bacteraemia in patients with febrile neutropenia. Scand J Infect Dis. 2004;36:365–371
  19. von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, et al. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis. 2004;23:539–544
  20. Rintala E, Remes K, Salmi TT, Koskinen P, Nikoskelainen J. The effects of pretransplant conditioning, graft-versus-host disease and sepsis on the CRP levels in bone marrow transplantation. Infection. 1997;25:335–338
  21. Schots R, Kaufman L, Van Riet I, et al. Monitoring of C-reactive protein after allogeneic bone marrow transplantation identifies patients at risk of severe transplant-related complications and mortality. Bone Marrow Transplant. 1998;22:79–85
  22. Schots R, Van Riet I, Ben Othman T, et al. An early increase in serum levels of C-reactive protein is an independent risk factor for the occurrence of major complications and 100-day transplant-related mortality after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2002;30:441–446
  23. Min CK, Kim SY, Eom KS, et al. Patterns of C-reactive protein release following allogeneic stem cell transplantation are correlated with leukemic relapse. Bone Marrow Transplant. 2006;37:493–498
  24. Pihusch M, Pihusch R, Fraunberger P, et al. Evaluation of C-reactive protein, interleukin-6, and procalcitonin levels in allogeneic hematopoietic stem cell recipients. Eur J Haematol. 2006;76:93–101
  25. Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–828
  26. Cooke KR, Gerbitz A, Crawford JM, et al. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest. 2001;107:1581–1589

PII: S1083-8791(08)00087-6

doi: 10.1016/j.bbmt.2008.02.008

Biology of Blood and Marrow Transplantation
Volume 14, Issue 5 , Pages 510-517 , May 2008

Article Tools

* Image Usage & Resolution